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ABSTRACT
Background. There is significant interest in the use of
stereotactic ablative radiotherapy (SABR) as a treatment
modality for liver metastases. A variety of SABR frac-
tionation schemes are in clinical use. We conducted a
phase I dose-escalation study to determine the maximum
tolerated dose of single-fraction liver SABR.
Methods. Patients with liver metastases from solid tu-
mors, for whom a critical volume dose constraint could be
met, were treated with single-fraction SABR. Seven pa-
tients were enrolled to the first group, with a prescription
dose of 35 Gy. Dose was then escalated to 40 Gy in a
single fraction, and seven more patients were treated at this
dose level. Patients were followed for toxicity and under-
went serial imaging to assess lesion response and local
control.
Results. Fourteen patients with 17 liver metastases were
treated. There were no dose-limiting toxicities observed at
either dose level. Nine of the 13 lesions assessable for
treatment response showed a complete radiographic re-
sponse to treatment; the remainder showed partial
response. Local control of irradiated lesions was 100 % at a
median imaging follow-up of 2.5 years. Two-year overall
survival for all patients was 78 %.
Conclusions. For selected patients with liver metastases,
single-fraction SABR at doses of 35 and 40 Gy is tolerable
and shows promising signs of efficacy at intermediate
follow-up.
Dissemination to the liver is a common event in the
metastatic progression of many types of tumors. In a subset
of patients, local therapies, such as surgery directed to
metastatic lesions growing in the liver, may lead to pro-
longed disease-free survivals beyond what would be
expected with systemic therapy alone.1,2 For the treatment
of colorectal cancer, it is well established that complete
surgical extirpation of hepatic metastases can yield long-
term disease-free survival in a significant proportion of
selected patients. In patients with oligometastatic disease
states where the metastatic burden is limited to the liver,
removal or ablation of these tumors may lead to cure.3
Surgical intervention is limited to a selected group of
patients who are candidates based on medical operability
and also have resectable disease with sufficient hepatic
reserve. As a result, there is a growing variety of minimally
invasive treatment alternatives to resection for the man-
agement of liver metastases. These treatments have
primarily taken the form of thermal ablation, most com-
monly radiofrequency ablation (RFA). RFA has yielded
good local control results, in particular for smaller (\3 cm)
tumors removed from large blood vessels where the heat-
sink effect limits ablative temperatures.4,5
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Recent developments in radiation treatment planning
techniques and technologies have allowed for the applica-
tion of stereotactic ablative radiotherapy (SABR), which
delivers potent radiation doses to discrete tumors with
rapid fall-off of dose in surrounding normal tissues, to
targets in the lung, liver, and other organs. SABR delivered
in one fraction (one treatment) is a promising approach for
many reasons. Single-fraction treatment is highly conve-
nient for patients and efficient, leading to minimal
interruption in planned systemic therapies for patients with
metastatic cancer. Herfarth and colleagues reported an
early experience with single-fraction SABR, escalating the
prescription dose from 14 to 26 Gy with promising safety
and early efficacy results.6 Authors from the same institu-
tion recently reported a series of 138 liver tumors in 90
patients treated with single-fraction therapy, with pre-
scription doses as high as 30 Gy.7 With a median dose of
24 Gy, local control at 18 months was 59 %. Patients with
colorectal primary tumors had worse local control rates
relative to breast primary tumors. Goodman and colleagues
safely escalated single-fraction irradiation from 18 to
30 Gy for patients with primary and secondary liver tu-
mors.8 Local control was 77 % at 1 year.
These series imply that higher radiation doses may be
necessary for optimal tumor control. However, the safety
and tolerability of higher-dose single-fraction radiation
treatments for liver tumors is unclear. Therefore, we con-
ducted a phase I clinical dose-escalation trial to determine
the tolerability of single-fraction SABR in the liver. In this
report, we detail treatment-related toxicities of this
approach as well as treatment efficacy results.
METHODS
Patient Eligibility
This phase I clinical trial was approved by the UT
Southwestern institutional review board. Adult patients
with Zubrod performance status of 2 or less, with 5 or
fewer liver metastases (non-germ cell or hematologic
origin) were eligible for enrollment. Patients had to have an
expected life span of at least 6 months and could not have
received prior liver radiation, which would lead to ex-
ceeding protocol-defined constraints for the liver and other
normal tissues. Patients underwent multidisciplinary eval-
uation for consideration of liver-directed therapies. The
treated tumor(s) had to be located outside of the central
liver zone, defined as a 2-cm expansion around the course
of the portal vein contoured to its bifurcation in the liver.
Patients were not eligible if they had significant and un-
controlled active comorbidities, including any or all of the
following: unstable angina and/or congestive heart failure
or myocardial infarction within the preceding 6 months;
COPD exacerbation or acute infection at the time of reg-
istration; or active hepatitis or Child’s-Pugh class B or C
cirrhosis. Patients’ laboratory values had to meet these
restrictions: hemoglobin C10 g/dL, Platelets C100,000 per
microliter, ANC C1000 per microliter; albumin[3 g/dL,
alkaline phosphatase, ALT, AST, total bilirubin, and PT/
INR B1.5 times the upper limit of normal. A critical liver
volume constraint also had to be met with the single-
fraction radiation treatment plan: at least 700 cc of normal
liver had to receive \9.1 Gy. Steroid premedication was
encouraged.
Radiation Dose Escalation
The radiation prescription dose was escalated in incre-
ments of 5 Gy. The starting dose was 35 Gy. Dose-limiting
toxicity (DLT) was defined according to the National
Cancer Institute Common Toxicity Criteria for Adverse
Events (CTCAE). Treatment-related grade 3, 4, or 5 gas-
trointestinal, hepatobiliary/pancreatic, renal/genitourinary,
or neurologic toxicity was considered dose-limiting toxi-
city, as were any grade 4 or 5 toxic events in these
categories: blood/bone marrow, cardiac, pulmonary/upper
respiratory, metabolic/laboratory, musculoskeletal/soft tis-
sue, and skin. Any other grade 4 or 5 events that were
treatment-related also constituted DLT.
Patients were enrolled in cohorts of 7–15. If zero of the
first 7 patients, 2 or fewer of the first 9, 3 or fewer of the
first 12, or 4 or fewer of the first 15 experienced DLT
within the first 90 days following treatment, the dose level
was escalated. The maximum tolerated dose level was
established as the tolerated dose level below which
excessive DLTs (at a rate C33 %) had been reached.
Single-Fraction SABR Planning and Delivery
Patients were immobilized in a full-body, vacuum-lock
mold, which was placed in a stereotactic body frame
(Elekta, Stockholm, Sweden). Respiratory motion was
assessed with fluoroscopy and motion of the diaphragm was
limited to\1 cm with the use of abdominal compression as
needed. Placement of fiducials to assess motion and guide
radiation delivery was allowed but not required. A four-
dimensional computed tomography (CT) scan was obtained
to aid in delineation of the motion envelope of the gross
tumor volume. A magnetic resonance imaging (MRI) scan
of the abdomen, unless contraindicated, was recommended
to aid in delineation of the tumor for treatment planning.
This scan could serve as a baseline image set for assessment
of treatment response. Expansions of 5 mm in the axial
plane and 5–10 mm in the cranio-caudal plane around the
GTV were made to generate a planning target volume
(PTV). Both three-dimensional (3D) conformal radiation
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treatments and intensity-modulated radiation therapy with
megavoltage photons could be used for treatment planning.
For the 3D conformal treatments, multiple noncoplanar
beams were used, with minimal block margin surrounding
the PTV. As such, prescription isodose lines for these plans
could be to the 60–90 % isodose line. Planning guidelines
called for 95 % of the PTV to be covered by the prescription
dose and 99 % of the PTV to receive a minimum of 90 % of
the prescription dose. Normal tissue dose delivery guideli-
nes for bowel, skin, lung, and kidney were provided to
facilitate planning but could be exceeded at the discretion of
the treating physician. The liver critical volume and spinal
cord constraints had to be respected in all cases. Normal
tissue constraints are shown in Table 1.
Follow-up
Patients were followed at 4–6 weeks and at 3 months
following treatment, with subsequent follow-up visits
every 3 months through 1 year. Then, patients were fol-
lowed every 6 months through 5 years of follow-up, and
annually thereafter. At the time of follow-up, imaging of
the abdomen, preferably with MRI, was obtained, as were
the following: serum chemistries and PT/INR.
Local control was defined as lack of tumor growth on
imaging studies within the treated tumor volume. Pre- and
post-SABR MRI scans were reviewed to assess control on
a per-lesion basis. T2-weighted axial images were followed
as these images most consistently and clearly delineated
the target tumor for radiation treatment planning. Follow-
up and survival were calculated from the day of radiation
treatment.
Treatment with systemic therapy was allowed both
before and after the single-fraction SABR treatment.
However, it had to be held for 6 days before, during, and
5 days after the delivery of the radiation.
Primary and Secondary End Points
The primary end point of this study was to establish a
maximum tolerated dose for single-fraction irradiation of
liver metastases. The initial goal was to escalate to a dose
of 50 Gy if dose-limiting toxicities were not prohibitive at
lower doses. However, with feasibility issues, including
patient accrual as well as the local control results obtained
at 40 Gy, further escalation beyond 40 Gy was not
undertaken. Secondary endpoints included local control of
the treated lesions and overall survival.
RESULTS
Patient Characteristics
Patient and tumor characteristics are shown in Table 2.
Fourteen patients with 17 liver metastases were treated:
seven at the first dose level (35 Gy) and seven at the second
TABLE 1 Normal tissue dose constraints
Structure Constraint
Uninvolved liver 700 mL receives\9.1 Gy
Spinal cord \0.35 mL exceeds 10 Gy
\1.2 mL exceeds 7 Gy
Maximum allowed point dosea: 14 Gy
Stomach \10 mL exceeds 11.2 Gy
Maximum allowed point dose: 12.4 Gy
Duodenum \5 mL exceeds 11.2 Gy
\10 mL exceeds 9 Gy
Maximum allowed point dose: 12.4 Gy
Jejunum/ileum \5 mL exceed 11.9 Gy
Maximum allowed point dose: 15.4 Gy
Colon \20 mL exceed 14.3 Gy
Maximum allowed point dose: 18.4 Gy
Skin \10 mL exceed 23 Gy
Maximum allowed point dose: 26 Gy
a Point dose = 0.035 mL
TABLE 2 Patient and tumor features
Characteristic Value
Number of patients
Dose level 1 (35 Gy) 7





Male 9 (64.3 %)
Female 5 (35.7 %)
Primary site
Renal 5 (35.7 %)
Colorectal 3 (21.4 %)
Melanoma 2 (14.3 %)
Nasopharynx 1 (7.1 %)
Lung 1 (7.1 %)
Breast 1 (7.1 %)
Endometrial 1 (7.1 %)
Number of tumors 17
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level (40 Gy). Patients had a variety of primary tumor sites.
Three patients had two liver metastases treated. None of
the tumors abutted the inferior vena cava. One treated tu-
mor abutted the left hepatic vein.
Toxicity
There were no treatment-related grade 3, 4, or 5 events
at either dose level. A patient in the 40-Gy group devel-
oped grade 2 nausea and vomiting as well as a grade 2
increase of alkaline phosphatase, all of which were con-
sidered related to the radiation treatment. All other patients
had at worst grade 1 toxicity events (toxicity outcomes are
shown in Table 3). Thus, there were no DLT events as
defined by the protocol. Four patients developed postra-
diation biliary stenosis adjacent (peripheral) to the treated
tumor: two patients in each dose group. In two cases this
was segmental stenosis, and in two cases it was
subsegmental. No intervention was required in any of these
cases. Four patients with tumors near the liver dome
developed asymptomatic imaging changes in the lung ad-
jacent to the dome.
Tumor Response and Local Control
Eleven of the 14 patients had baseline MRI scans ob-
tained before the SABR treatment, and all patients had
MRI obtained at follow-up visits as per the protocol
guidelines. Applying RECIST criteria in the MRI-based
assessment of irradiated liver metastases is challenging,
because there are multiple sequences obtained with MRI.9
We assessed response based on consistent imaging se-
quences (T2) across the studies. Using this criteria, and
based on the 13 treated metastases, which were C1 cm on
baseline imaging and which had both pre- and posttreat-
ment MR assessment, the median imaging follow-up time
was 2.5 (range 0.5–3.0) years. None of these 13 tumors had
evidence for local progression at the time of last follow-up;
thus, treated lesion local control was 100 %. Nine of these
13 (69 %) tumors demonstrated a complete response, and 4
of these 13 (31 %) tumors demonstrated a partial response
at the time of last imaging follow-up. Figure 1 demon-
strates the imaging evolution of one of the liver metastases
treated in this study.
Allowing for CT-to-MRI comparisons as well as com-
parison of lesions \1 cm in size, the median imaging
follow-up for all 17 of the treated lesions was 2.5 (range
0.5–3.5) years. In this analysis, local control was again
100 % with no tumor showing local progression at the time
of last follow-up
Survival
Nine of 14 treated patients were still alive at the time of
survival analysis. Figure 2 shows Kaplan–Meier survival
FIG. 1 Radiographic response of a treated liver metastasis. The
patient had a diagnosis of metastatic non-small cell lung cancer with
evidence for a liver metastasis in segment 6. The left panel shows the
pretreatment T2 fat-saturated image with the lesion noted by the
arrow. The central panel shows the treated lesion approximately
6 weeks following radiation (35 Gy). The right panel shows the
lesion approximately 6 months following radiation, with no evidence
of residual tumor
TABLE 3 Toxicities
Toxicity Grade 1 Grade 2
Fatigue 4 0
Alkaline phosphatase increased 5 1
Abdominal pain 1 0





Aspartate aminotransferase increased 2 0
Alanine aminotransferase increased 2 0
Chest wall pain 2 0
Bile duct stenosis 4 0
a All toxicities deemed at least possibly related to the stereotactic
radiation treatment. Some patients had multiple toxicities and these
are separately documented in this table
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curves for all 14 patients and patients grouped by dose
levels. Five of the 14 treated patients have died. None of
the deaths were deemed treatment-related. Estimated 2-
year overall survival was 78 %.
DISCUSSION
A variety of ablation technologies are available to treat
tumors, including foci of metastatic disease, as alternatives
to surgery. SABR is increasingly well established as a
treatment therapy for tumors in the lung, liver, prostate,
kidney, bone, and other organs.8,10–22 Liver tumors were
one of the first types of neoplasm treated with SABR.
Blomgren and colleagues reported an early series with
different hypofractionated regimens in the mid-1990s.23
Subsequently, there have been clinical investigations into
various high-dose hypofractionation regimens.8,11–17
Because the liver has features of a parallel-structured
organ, at least in its periphery, tolerance to partial volume
liver irradiation is substantially higher relative to whole-
volume irradiation.24 Also, it is established that a limitation
imposed on surgery for liver metastases relates to the re-
quirement to leave a remnant of liver parenchyma that is
sufficient to maintain immediate hepatic function.25 In our
study, we used a baseline ‘‘critical volume’’ of liver
thought necessary to maintain baseline liver function. In
addition, a tolerance dose, in essence a threshold dose, was
defined above which liver parenchyma would be sig-
nificantly damaged. Liver parenchyma exposed to doses
below the tolerance dose could contribute to the critical
volume and would be assumed to maintain essential hep-
atic function after the treatment. This same model tested in
our current trial’s design allowed high levels of dose
escalation in previous phase I trials for SABR treatment of
liver metastases using 3 and 5 fractions.11,12
High-dose radiation treatments, including single-fraction
SABR, may eradicate tumors through stromal effects not
predicted by classical radiation biology considerations.26–28
Investigators from Memorial Sloan-Kettering have reported
significantly improved local control for doses in the 23–
24 Gy range relative to lower doses.29–32 It is possible that
doses higher than this are required as a function of tumor
histology and location, because doses in the range of
[20 Gy have not always been associated with high and
durable local tumor control rates in other series. Thus, phase
I dose escalation studies such as our own are warranted.
In our study, we escalated the radiation dose from 35 to
40 Gy in a single fraction for tumors outside of the central
liver zone, which we defined as a 2-cm shell surrounding
the portal vein to its bifurcation in the liver. We chose this
selection criteria based on concern that the liver may
demonstrate features of a radiation-sensitive, serial-struc-
tured organ near its hilum. Prior experience in treatment of
central lung tumors (lesions near the major mainstem
bronchi) demonstrated excessive toxicity for severely hy-
pofractionated treatment courses relative to what was seen
with tumors in the lung periphery.33 Therefore, it seemed
prudent to exclude central liver tumors from high-dose
single-fraction treatments, although a separate clinical
study, or possibly preclinical study, would be necessary to
determine if the structures in the hilum of the liver exhibit
sensitivity similar to the lung hilum.
We used serial MR imaging to follow the response of
treated lesions and observed promising local control results
at both dose levels. The response of both tumors and nor-
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FIG. 2 a Overall survival curve for all treated patients. b Overall survival curve for the two dose groups
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is not well described in the literature, and application of
RECIST criteria to tumors followed with MR imaging is
challenging because of the multitude of sequences obtained
with scans. We used consistent sequences (T2) to follow
patients from baseline through serial follow-up. Further
follow-up and study will help to determine if the excellent
local control rates are sustained and will aid in determining
if stereotypical imaging responses of tumor and normal
tissue following high-dose radiation are observed and
correlated with long-term tumor control and normal liver
injury.
CONCLUSIONS
With the selection criteria used in our study design, we
were able to safely escalate single fraction SABR for liver
metastases to 40 Gy. Based on these results, we propose
that this is a safe and apparently effective alternative to
multi-fraction SABR courses for well-selected patients
with liver metastases.
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